Multi-peg Lipid Compounds for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liposomal delivery systems face challenges in achieving stable cell culture or in vivo stability, efficient targeting of cells and intracellular compartments, and effective release of encapsulated materials, particularly in delivering nucleic acids to various cell types and tissues with reduced toxicity.
Innovation Solution
Development of novel lipid compounds comprising a lipid substructure with a hydrophobic moiety and hydrophilic moiety, combined with two or more polymeric groups such as PEG, to enhance transfection efficiency, cellular uptake, and intracellular release of nucleic acids, while improving pharmacokinetic properties and biodistribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional liposomal delivery systems are used, then nucleic acid delivery is achieved, but transfection efficiency and cellular uptake are insufficient
Solution Approach 1:
The patent applies composite materials by combining lipid substructures with multiple polymeric groups (such as PEG chains) to create hybrid delivery vectors. This composite structure integrates the membrane-fusion capability of lipids with the stability and solubility enhancement provided by polymeric groups, thereby simultaneously improving transfection efficiency and delivery stability.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of delivery vectors through varying the number, length, and configuration of polymeric groups attached to lipid substructures. By adjusting these molecular parameters, the patent optimizes both cellular uptake efficiency and in vivo stability, resolving the contradiction between transfection efficiency and delivery reliability.
2Productivity
If liposomal delivery systems are used, then nucleic acid delivery is achieved, but toxicity remains high
Solution Approach 1:
The patent applies local quality by introducing hydrophilic polymeric groups at specific locations on the lipid structure, particularly on the outer surface of the liposome. This localized modification creates regions of different properties: the lipid core maintains membrane-disrupting capability for efficient delivery, while the surface polymeric groups provide steric stabilization and reduced immunogenicity, thereby lowering toxicity without compromising delivery efficiency.
3Ease of manufacture
If simple lipid structures are used, then ease of manufacture is maintained, but targeting capability and intracellular release are insufficient
Solution Approach 1:
The patent applies segmentation by dividing the delivery vector into distinct functional modules: a lipid substructure providing membrane interaction capability, and separate polymeric groups providing targeting and stability functions. This modular segmentation allows each component to be optimized independently while maintaining overall manufacturability, achieving both synthesis simplicity and enhanced targeting capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate enhanced transfection efficiencies, reduced toxicity, and improved pharmacokinetic properties, enabling targeted and efficient delivery of nucleic acids to various cells and tissues, thereby improving therapeutic outcomes.
Implementation Method 1
a lipid substructure comprising a hydrophobic moiety and a hydrophilic moiety
Implementation Method 2
two or more polymeric groups such as PEG
Data Source
AI summary
The compounds disclosed herein (e.g., compounds of Formula (I), (II), (III), and (IV)) comprise a lipid substructure comprising a hydrophobic moiety and a hydrophilic moiety; and two or more polymeric groups (e.g., two or more polyethylene glycol (PEG) groups). The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.